Abstract
Over the last 30 years Myasthenia Gravis (MG) has become amenable to successful treatment, primarily from the remarkable advances in our understanding of the biology of neuromuscular transmission and of pathogenic processes underlying the disorder [1–5]. With treatment, today, most patients can expect to lead normal or nearly normal lives. Some cases of MG may go into remission temporarily, and muscle weakness may disappear so that medications can be discontinued.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Grob D, Brunner N, Namba T, Pagala M (2008) Lifetime course of myasthenia gravis. Muscle Nerve 37:141–149
Conti-Fine BM, Milani M, Kaminsk HJ (2006) Myasthenia gravis: Past, present, and future. J Clin Invest 116:2843–2854
Hirsch NP (2007) Neuromuscular junction in health and disease. Br J Anaesth 99:132–138
Mahadeva B, Phillips LH, Juel VC (2008) Autoimmune disorders of neuromuscular transmission. Semin Neurol 28:212–227
Juel VC, Massey JM (2007) Myasthenia gravis. Orphannet J Rare Dis 2:44
Keesey JC (2004) A history of treatments for myasthenia gravis. Semin Neurol 24:5–16
Pascuzzi RM (1994) The history of myasthenia gravis. Neurol Clin 12:231–242
Hughes T (2005) The early history of myasthenia gravis. Neuromuscul Disord 15:878–886
Jaretzki A, Barohn RJ, Ernstoff RM et al (2000) Myasthenia gravis: Recommendations for clinical research standards. Ann Thorac Surg 70:327–334
Benatar M (2006) A systematic review of diagnostic studies in myasthenia gravis. Neuromusc Dis 16:459–467
Richman DP, Agius MA (2003) Treatment principles in the management of autoimmune Myasthenia Gravis. Ann NY Acad Sci 998:457–472
Hilton-Jones D, Palace J (2005) The management of myasthenia gravis. Pract Neurol 5:18–27
Skeie GO, Aposolski S, Evoli A et al (2006) Guidelines for the treatment of autoimmune neuromuscular transmission disorders. Eur J Neur 13:691–699
Hilton-Jones D (2007) When the patient fails to respond to treatment: myasthenia gravis. Pract Neurol 7:405–411
National Institute of Neurological Disorders and Stroke. http://www.ninds.nih.gov/disorders/myasthenia_gravis/myasthenia_gravis.htm, http://www.myasthenia.org/
Mendiratta MM, Kuntzer T, Pandey S (2008) Anticholinesterase treatment for myasthenia gravis (Protocol). Cochrane Databases of Systematic Reviews, Issue 1
Schneider-Gold C, Gajdos P, Tojka KV, Hohlfeld RR (2005) Corticosteroids for myasthenia gravis. Cochrane Databases of Systematic Reviews, Issue 2
Gajdos P, Chevret S, Toyka K (2002) Plasma exchange for myasthenia gravis (review). Cochrane Databases of Systematic Reviews, Issue 1
Gajdos P, Tranchant C, Clair B et al (2005) Treatment of myasthenia gravis exacerbation with intravenous immunoglobulin. A randomized double-blind clinical trial. Arch Neurol 62:1689–1693
Gajdos P, Chevret S, Toyka K (2006) Intravenous immunoglobulin for myasthenia gravis (review). Cochrane Databases of Systematic Reviews, Issue 1
Gronseth GS, Barohn RJ (2000) Practice parameter: Thymectomy for autoimmune myasthenia gravis (an evidence based review). Neurology 55:7–15
Shahrizaila N, Pacheco OA, Vidal DG et al (2005) Thymectomy in myasthenia gravis: Comparison of outcome in Santiago, Cuba and Nottingham, UK. J Neurol 252:1262–1266
Hart IK, Sathasivam S, Sharshar T (2007) Immunosuppresive agents for myasthenia gravis. Cochrane Databases of Systematic Reviews, Issue 4
Ciafaloni E, Massey JM, Tucker-Lipscomb B, Sanders DB (2001) Mycophenolate mofetil for myasthenia gravis: An open-label pilot study. Neurology 56:97–99
Meriggioli MN, Ciafaloni E, Al-Hayk KA et al (2003) Mycophenolate mofetil for myasthenia gravis. An analysis of efficacy, safety and tolerability. Neurology 61:1438–1440
Kakoulidou M, Bjelak S, Pirskanen R, Lefvert AK (2007) A clinical and immunological study of myasthenia gravis treated with infliximab. Acta Neurol Scand 115:279–283
Hoff JM, Daltveit AK, Gilhus NE (2007) Myasthenia gravis in pregnancy and birth: Identifying risk factors, optimising care. Eur J Neurol 14:38–43
Agius MA (2000) Treatment of ocular myasthenia with corticosteroids. Arch Neurol 57:750–751
Kaminski HJ, Daroff R (2000) Treatment of ocular myasthenia. Steroid only when compelled. Arch Neurol 57:752–753
Benatar M, Kaminski H (2006) Medical and surgical treatment for ocular myasthenia. Cochrane Databases of Systematic Reviews, Issue 1
Benatar M, Kaminski HJ (2007) Evidence report: The medical treatment of ocular myasthenia (an evidencebased review). Neurology 68:2144–2149
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2008 Springer-Verlag Italia
About this chapter
Cite this chapter
Gentile, R., Capone, L., Schoenhuber, R. (2008). Thymus-related Myasthenia Gravis. Multimodal Therapy and Follow-up. In: Lavini, C., Moran, C.A., Morandi, U., Schoenhuber, R. (eds) Thymus Gland Pathology. Springer, Milano. https://doi.org/10.1007/978-88-470-0828-1_29
Download citation
DOI: https://doi.org/10.1007/978-88-470-0828-1_29
Publisher Name: Springer, Milano
Print ISBN: 978-88-470-0827-4
Online ISBN: 978-88-470-0828-1
eBook Packages: MedicineMedicine (R0)